Remove 2023 Remove Marketing Remove Safety
article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.

article thumbnail

PDUFA Delay: FDA Asks for More Information From Abeona for Pz-cel Market Application

The Dermatology Digest

The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel. The BLA for pz-cel was accepted for filing and granted priority review designation by the FDA in November 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.

article thumbnail

8 Best Vitamin D3 with K2 Supplements 2023: Benefits, Reviews and Prices

Aesthetics Advisor

Vitamin D Market Size The Global Vitamin D Market size was worth US$ 1.1 between 2023 and 2028. Related: Nutritional Synergies of Vitamin D, K2 and Magnesium Best Vitamin D3 and K2 Supplement Brands in 2023 We have done our research and shortlisted the best for you. Vitamin D is found in cells throughout the body.

article thumbnail

TDD Media Partner AARS Responds to the Valisure Citizen Petition on Benzene in Benzoyl Peroxide Drug Products

The Dermatology Digest

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS. Right now, there are many questions about this issue. pp 9767-9777.

Rosacea 64
article thumbnail

A comment on the 2024 EWG Sunscreen Guide; Is EWG actively harming safe consumer sun protection?

The Eco Well Blog

Or are they putting these guides out as a fear marketing campaign to promote the EWG seal program (which makes them money)? 2023), when consumers had the option between “mineral” and “chemical” sunscreens, when blinded, overwhelmingly they preferred the “chemical” sunscreen. market while tests are still being conducted.

article thumbnail

FDA Nod for Ustekinumab Biosimilar

The Dermatology Digest

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. and worldwide.